High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

NCT06971406 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER_GOV

Sponsor class

Conditions

Non Small Cell Lung Cancer
EGFR Mutation
Leptomeningeal Metastases
Targeted Therapy

Interventions

DRUG: Combination therapy prospective cohort

Sponsor

Qiming Wang